Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Senderra.												
	3	Gastrointest			escriber:		NPI:					
		Enrollment F	orm	Su	pervising Physicia	an:	NPI:					
CENIDEDDA		Dhysisian O	fiasa Call		dress:		Tax ID:					
		Physician Offices Call 855-460-7928										
Specialty Pharmacy 3712 E. Plano Parkway, Ste. 200 Fax: 888-777			EGAE		Phone: Fax:							
Plano, TX 75074	is to be sent & received via fax	Fax: 888-777	-5645	Cor	Contact:							
This prescription form	is to be sent a received via rax				TIENT INFORMA							
Name:		□ M		rans M	☐ Trans F ☐ Oth	er DOB:	,	1		SS#:		
Street:		l l		City:		State:		ZIP:				
Phone: Alt. Phone:				☐ English ☐ Spanish ☐ Other: Wt.: Ht.:						Ht.:		
PRESCRIPTION												
Has the patient received a loading dose/starter kit? Yes Start Date: /_ / DNo SHIP TO: Patient's Home Doctor's Office Other:												
Drug	<u> </u>			Directions & Quantity								
☐ 300 mg/15 mL Vial			☐ INITIAL: Infuse 300 mg via IV at week 0, 4, and 8 (Quantity: 1 with 2 refills)									
Omvoh™	☐ 100 mg Pen		MAINTENANCE: Inject 200 mg (two 100 mg injections) SQ 4 weeks after final initial dose (week 12), then every 4 weeks thereafter (Quantity: 1)									
		g		Initial: Take 45 mg PO once daily (Quantity: 28 with 1 refill) ***Intended for patients with Ulcerative Colitis***								
Rinvoq®	45 mg Tablets		☐ INITIAL: Take 45 mg PO once daily (Quantity: 28 with 1 refills) ***Intended for patients with Crohn's disease***									
	15 mg Tablets		☐ MAINTENANCE: Take 15 mg PO once daily (Quantity: 30)									
	30 mg Tablets		☐ MAINTENANCE: Take 30 mg PO once daily (Quantity: 30)									
Simponi®	☐ 100 mg SmartJect® Pen		□ INITIAL: Inject 200 mg SQ at week 0, then 100 mg at week 2 (Quantity: 3)									
	☐ 100 mg Pre-filled Sy	■ MAINTENANCE: Inject 100 mg SQ every 4 weeks (Quantity: 1)										
Skyrizi [®]	600 mg/10 mL Vial		☐ INITIAL: Infuse 600 mg via IV at week 0, 4, and 8 (Quantity: 1 with 2 refills)									
	180 mg/1.2 mL Pre-filled cartridge via On-Body Injector		MAINTENANCE: Inject 180 mg SQ 4 weeks after final initial dose (week 12), then every 8 weeks thereafter (Quantity: 1)									
	☐ 360 mg/2.4 mL Pre-filled cartridge		MAINTENANCE: Inject 360 mg SQ 4 weeks after final initial dose (week 12), then every 8 weeks									
	via On-Body Injector		thereafter (Quantity: 1) INITIAL INTRAVENOUS DOSAGE: A single intravenous infusion using weight-based dosing: Up to									
04.1	130 mg/26mL Vial		55kg=260 mg (2 vials), >55kg to 85kg=390 mg (3 vials), >85kg=520 mg (4 vials)									
Stelara®	Pre-filled Syringe		☐ MAINTENANCE: Inject 90 mg SQ 8 weeks after initial dose, then every 8 weeks thereafter (1 syringe)									
Weight Required: MEDICAL INFORMATION												
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY												
PREVIOUS THERAPIES: Tried & Failed			•						traindication:			
☐ Methotrexate ☐ (-		
Cimzia	OIITIZIA										-	
\										-		
K50.00 Crohn's disease of small intestine, without complications												
K50.80 Crohn's disease of both intestines, without complications												
K51.80 Other Ulcerative Colitis, without complications Cher:												
Other:									_			
Date of Diagnos		Allergies:	•									
Active TB is ruled out:												
Additional Clinic	cal Information:											
INJECTION TRAINING												
□ Patient has received pen and injection training □ Physician's office to provide injection training □ Senderra to coordinate injection training												
To Prescriber: By s	signing this form and utilizing	our services vou ar		PR	ESCRIBER SIGNA	TURE		nated agent in de	ealing with	medical and prescription insuran	ce	
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription is companies, and co-pay assistance foundations. Prescriber: Date:										2.500. G.10 procenphon insulan		
Prescriber:								^D	ate:	1 1		
CONFIDENTIALITY NOTICE IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named												
	uld not disseminate, distribute										nanteu	